BG
TRIB

Bahl & Gaynor’s Trinity Biotech TRIB Stock Holding History

Bahl & Gaynor’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,273
Closed -$251K – 422
2015
Q4 		$251K Sell
4,273
-3,136
-42% -$185K ﹤0.01% 388
2015
Q3 		$423K Buy
7,409
+1,002
+16% +$80.6K 0.01% 333
2015
Q2 		$578K Buy
6,407
+293
+5% +$25.4K 0.01% 307
2015
Q1 		$588K Buy
6,114
+4,025
+193% +$372K 0.01% 281
2014
Q4 		$183K Sell
2,089
-3,582
-63% -$309K ﹤0.01% 408
2014
Q3 		$519K Buy
5,671
+781
+16% +$84.6K 0.01% 279
2014
Q2 		$563K Buy
4,890
+10
+0.2% +$1.19K 0.01% 264
2014
Q1 		$591K Buy
4,880
+211
+5% +$27.7K 0.01% 256
2013
Q4 		$587K Buy
4,669
+376
+9% +$45.1K 0.01% 242
2013
Q3 		$467K Buy
+4,293
New +$418K 0.01% 254

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Bahl & Gaynor's TRIB Position: Q1 2016 in Review

Bahl & Gaynor sold out of Trinity Biotech (TRIB) in Q1 2016, closing a stake of 4,273 shares — an estimated $251K sold.

Bahl & Gaynor first reported a position in TRIB in Q3 2013 and held it in 10 quarters. The position peaked at $591K in Q1 2014. 79 funds tracked by Wall St. Rank hold TRIB as of Q1 2016.

  • Bahl & Gaynor reported no remaining Trinity Biotech position as of Q1 2016 after selling out during the quarter.
  • Bahl & Gaynor sold 4,273 Trinity Biotech shares in Q1 2016, an estimated $251K.
  • Bahl & Gaynor first reported a position in Trinity Biotech in Q3 2013 and held it in 10 quarters.
  • Bahl & Gaynor's Trinity Biotech position peaked at $591K in Q1 2014.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2016.

Based on Bahl & Gaynor's 13F filing for Q1 2016, filed 10 May 2016.